Law Offices

Wilmington Research and Development Corp. has been a leading provider of custom electronic controls since 1978, catering to various industries with their high-quality, cost-efficient solutions. With a strong focus on both civil and military sectors, their expertise in hardware solutions has consistently outperformed traditional PLC-based control methods, offering smaller, cheaper, and superior alternatives. With an extensive portfolio of successful projects, Wilmington Research and Development Corp. brings a level of mastery to the table that is unmatched by many competitors, ensuring robust and reliable control systems tailored to meet industry-specific needs.Generated from the website

Kidde-Fenwal is a subsidiary of United Technologies Corporation, a worldwide technology company with a long history of pioneering advancements in aerospace, aviation, helicopter design, climate control, elevator design and hydrogen fuel cells. Kidde-Fenwal originated in 1966 when Walter Kidde & Company, a leading fire protection manufacturer in New Jersey, acquired Fenwal, a manufacturer of temperature and gas ignition controls. In 1989, Williams Holdings, a major British industrial corporation, acquired Fenwal and the other Kidde fire protection companies. Following the acquisition, the new company was renamed Kidde-Fenwal. The company was one of the first to manufacture a laser-based smote detection system and a gas ignition system. Kidde-Fenwal is headquartered in Ashland, Mass.

ProTom International, based in North Reading, MA, is dedicated to transforming cancer treatment by enhancing the accessibility of proton therapy and advancing proton tomography technology. Their flagship product, the Radiance 330 Proton Therapy System, offers a compact and modular solution for healthcare providers, enabling the development of single or multiple-room capabilities within existing radiation oncology departments. The Radiance 330 features advanced pencil beam scanning technology and a compact synchrotron particle accelerator, providing a clinical treatment energy range from 70 MeV to 250 MeV, with future potential for proton imaging. ProTom's innovative approach aims to break down barriers and elevate the standards of proton therapy technology in the healthcare sector. Generated from the website